Walter H Gotlieb

Summary

Affiliation: McGill University
Country: Canada

Publications

  1. pmc Controversies in the treatment of early stage endometrial carcinoma
    Joshua Z Press
    Division of Gynaecologic Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada H3T 1E2
    Obstet Gynecol Int 2012:578490. 2012
  2. doi request reprint Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
    Walter H Gotlieb
    McGill University, Jewish General Hospital, Montreal, QC, Canada
    Lancet Oncol 13:154-62. 2012
  3. ncbi request reprint Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer
    Walter H Gotlieb
    Department of Gynecologic Oncology, Sheba Medical Center Tel Hashomer, Israel
    Gynecol Oncol 97:780-3. 2005
  4. ncbi request reprint Insulin-like growth factor receptor I targeting in epithelial ovarian cancer
    Walter H Gotlieb
    Division of Gynecologic Oncology, McGill University, Montreal, Quebec, Canada
    Gynecol Oncol 100:389-96. 2006
  5. ncbi request reprint Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer
    Walter H Gotlieb
    Department of Gynecologic Oncology, The Chaim Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel
    Obstet Gynecol 102:718-25. 2003
  6. ncbi request reprint The assessment and surgical management of early-stage vulvar cancer
    Walter H Gotlieb
    Sir Mortimer B Davis Hôpital Général Juif, McGill University, Montreal, Que, Canada
    Best Pract Res Clin Obstet Gynaecol 17:557-69. 2003
  7. ncbi request reprint Intraperitoneal chemotherapy: why the fuzz?
    Walter H Gotlieb
    Division of Gynecologic Oncology, McGill University and Segal Cancer Center, Jewish General Hospital, Montreal, Quebec, Canada
    Int J Gynecol Cancer 20:S14-6. 2010
  8. ncbi request reprint Doxorubicin levels in the serum and ascites of patients with ovarian cancer
    W H Gotlieb
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, 3755 Cote Ste Catherine, Suite A 632, Montreal, QC H3T 1E2, Canada
    Eur J Surg Oncol 33:213-5. 2007
  9. doi request reprint In vitro metformin anti-neoplastic activity in epithelial ovarian cancer
    Walter H Gotlieb
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Gynecol Oncol 110:246-50. 2008
  10. doi request reprint Prospective quality of life outcomes following robotic surgery in gynecologic oncology
    Jeremie Abitbol
    Divison of Experimental Medicine, Department of Medicine, McGill University, Montreal, Canada
    Gynecol Oncol 134:144-9. 2014

Collaborators

Detail Information

Publications54

  1. pmc Controversies in the treatment of early stage endometrial carcinoma
    Joshua Z Press
    Division of Gynaecologic Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, Canada H3T 1E2
    Obstet Gynecol Int 2012:578490. 2012
    ..This paper will focus on the advantages of minimally invasive surgery, the value of lymphadenectomy including sentinel lymph node mapping, and some of the current controversies surrounding adjuvant chemotherapy and radiation...
  2. doi request reprint Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
    Walter H Gotlieb
    McGill University, Jewish General Hospital, Montreal, QC, Canada
    Lancet Oncol 13:154-62. 2012
    ..We present the final results of a multicentre study of the efficacy and safety of aflibercept, a potent inhibitor of both VEGF and placental growth factor, in the treatment of malignant ascites...
  3. ncbi request reprint Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer
    Walter H Gotlieb
    Department of Gynecologic Oncology, Sheba Medical Center Tel Hashomer, Israel
    Gynecol Oncol 97:780-3. 2005
    ..Evaluation whether Jewish founder mutations in BRCA predispose to borderline tumors as they do to early invasive ovarian cancers...
  4. ncbi request reprint Insulin-like growth factor receptor I targeting in epithelial ovarian cancer
    Walter H Gotlieb
    Division of Gynecologic Oncology, McGill University, Montreal, Quebec, Canada
    Gynecol Oncol 100:389-96. 2006
    ..Preclinical evaluation of the anti-neoplastic activity of an insulin-like growth factor I receptor (IGF-IR) kinase inhibitor in ovarian cancer...
  5. ncbi request reprint Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer
    Walter H Gotlieb
    Department of Gynecologic Oncology, The Chaim Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel
    Obstet Gynecol 102:718-25. 2003
    ..To evaluate the safety of fertility-sparing hormonal therapy for endometrial cancer in young patients...
  6. ncbi request reprint The assessment and surgical management of early-stage vulvar cancer
    Walter H Gotlieb
    Sir Mortimer B Davis Hôpital Général Juif, McGill University, Montreal, Que, Canada
    Best Pract Res Clin Obstet Gynaecol 17:557-69. 2003
    ..Molecular detection methods that reveal cancer cells in sites not detectable by routine histology have been introduced to evaluate sentinel lymph nodes and may eventually become part of the routine metastatic work-up...
  7. ncbi request reprint Intraperitoneal chemotherapy: why the fuzz?
    Walter H Gotlieb
    Division of Gynecologic Oncology, McGill University and Segal Cancer Center, Jewish General Hospital, Montreal, Quebec, Canada
    Int J Gynecol Cancer 20:S14-6. 2010
    ..Critical evaluation of the benefits of intraperitoneal (IP) chemotherapy...
  8. ncbi request reprint Doxorubicin levels in the serum and ascites of patients with ovarian cancer
    W H Gotlieb
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, 3755 Cote Ste Catherine, Suite A 632, Montreal, QC H3T 1E2, Canada
    Eur J Surg Oncol 33:213-5. 2007
    ..To investigate the diffusion and accumulation of doxorubicin metabolites in the ascites of patients with ovarian cancer following intravenous injection, as a model for intraperitoneal accumulation of drugs...
  9. doi request reprint In vitro metformin anti-neoplastic activity in epithelial ovarian cancer
    Walter H Gotlieb
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Gynecol Oncol 110:246-50. 2008
    ..Metformin, a commonly used drug in the treatment of type II diabetes, may reduce cancer risk and improve cancer prognosis. We evaluated its effect on epithelial ovarian cancer cell lines...
  10. doi request reprint Prospective quality of life outcomes following robotic surgery in gynecologic oncology
    Jeremie Abitbol
    Divison of Experimental Medicine, Department of Medicine, McGill University, Montreal, Canada
    Gynecol Oncol 134:144-9. 2014
    ..To characterize the health-related quality of life (HRQL) of patients undergoing robotic surgery for the treatment of gynecologic cancers...
  11. doi request reprint Impact of robotics on the outcome of elderly patients with endometrial cancer
    Vincent Lavoue
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Gynecol Oncol 133:556-62. 2014
    ..To evaluate the impact of introducing a robotics program on clinical outcome of elderly patients with endometrial cancer...
  12. doi request reprint Relationship between body mass index and robotic surgery outcomes of women diagnosed with endometrial cancer
    Susie Lau
    Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Int J Gynecol Cancer 21:722-9. 2011
    ..This is a prospective evaluation of the outcome of minimal invasive surgery using robotics in function of the body mass index (BMI) of patients...
  13. doi request reprint BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide
    Marie Claude Beauchamp
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Gynecol Oncol 115:193-8. 2009
    ..To evaluate the anti-neoplastic activity of BMS-536924, an IGF-1R inhibitor, in epithelial ovarian cancer and its capacity to potentiate the effect of a PARP inhibitor, 3-aminobenzamide...
  14. doi request reprint Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved
    Tamar Perri
    Department of Gynecologic Oncology, Sheba Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Int J Gynecol Cancer 21:72-8. 2011
    ..Preserving reproductive function in young patients with early endometrial cancer is an accepted concept today. The safety and feasibility of long-term conservative treatment, allowing more than 1 pregnancy, remain to be ascertained...
  15. doi request reprint Vaginal vault dehiscence after robotic hysterectomy for gynecologic cancers: search for risk factors and literature review
    Laura Drudi
    Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, Quebec, Canada
    Int J Gynecol Cancer 23:943-50. 2013
    ..We searched for risk factors in patients with gynecologic cancers and complemented this with a literature review...
  16. doi request reprint Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinoma
    Ilan Bruchim
    Division of Gynecologic Oncology, McGill SMBD Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, QC H3T 1E2, Canada
    Cancer Genet Cytogenet 190:66-70. 2009
    ..Recurrence rate in patients with epithelial ovarian cancer is seemingly associated with specific genetic alterations detected by CGH, but the specific genes involved and the implications of these findings await further studies...
  17. doi request reprint Outcome of robotic surgery for endometrial cancer as a function of patient age
    Xing Ziggy Zeng
    Division of Gynecologic Oncology, Jewish General Hospital, and Department of Undergraduate Medical Education, Faculty of Medicine, McGill University, Montreal, Quebec, Canada
    Int J Gynecol Cancer 25:637-44. 2015
    ..This study aimed to evaluate and compare robot-assisted surgical staging on clinical outcomes, including quality of life and survival, as a function of patient age...
  18. doi request reprint Relevance of the OCT1 transporter to the antineoplastic effect of biguanides
    Eric D Segal
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Biochem Biophys Res Commun 414:694-9. 2011
    ..These results suggest that there may be settings where drug uptake limits direct action of metformin on neoplastic cells, raising the possibility that metformin may not be the optimal biguanide for clinical investigation...
  19. doi request reprint Are endometrial polyps true cancer precursors?
    Tamar Perri
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Jewish General Hospital, Montreal, Quebec, Canada
    Am J Obstet Gynecol 203:232.e1-6. 2010
    ..The purpose of this study was to assess whether endometrial polyps (EMPs) represent cancer precursors...
  20. ncbi request reprint Clinical outcome of cystectomy compared with unilateral salpingo-oophorectomy as fertility-sparing treatment of borderline ovarian tumors
    Yoav Yinon
    Division of Gynecological Oncology, Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, Tel Hashomer, Tel Aviv University, Israel
    Fertil Steril 88:479-84. 2007
    ..To compare recurrence rates and fertility outcomes of patients with borderline ovarian tumors (BOTs) who underwent unilateral salpingo-oophorectomy with those of patients who underwent cystectomy only...
  21. doi request reprint Outcomes and cost comparisons after introducing a robotics program for endometrial cancer surgery
    Susie Lau
    Jewish General Hospital, Quebec, Canada
    Obstet Gynecol 119:717-24. 2012
    ..To evaluate the effect of introducing a robotic program on cost and patient outcome...
  22. doi request reprint Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins
    Amber Yasmeen
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada
    Gynecol Oncol 121:492-8. 2011
    ..The aims of the study were to evaluate the ability of metformin to induce apoptosis in epithelial ovarian cancer cell lines and to identify the pathways involved in this effect...
  23. ncbi request reprint Familial vs sporadic ovarian tumors: characteristic genomic alterations analyzed by CGH
    Ofir Israeli
    Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
    Gynecol Oncol 90:629-36. 2003
    ..Our purpose was to get an overview of the genetic events leading to the development of familial and sporadic ovarian tumors and to identify chromosomal regions that may contain genes important in tumor progression...
  24. doi request reprint Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines
    Ido Laskov
    Division of Gynecologic Oncology, Jewish General Hospital Segal Cancer Center, Lady Davis Institute of Medical Research and Department of Oncology, McGill University, Montreal, Quebec, Canada
    Int J Gynecol Cancer 26:1213-21. 2016
    ..Metformin, an effective oral antidiabetic drug, has been associated with decreased cancer risk and mortality. In this pilot study, we started to evaluate the effect of metformin on EMT in vivo and in vitro in endometrial cancer (EC)...
  25. doi request reprint Virtual reality robotic surgery simulation curriculum to teach robotic suturing: a randomized controlled trial
    Daniel J Kiely
    Experimental Surgery, McGill University, Montreal, Canada
    J Robot Surg 9:179-86. 2015
    ....
  26. doi request reprint Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer
    Ido Laskov
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada Segal Cancer Center, Lady Davis Institute of Medical Research, McGill University, Montreal, Quebec, Canada
    Gynecol Oncol 134:607-14. 2014
    ..Metformin has been associated with reduced cancer risk. The mechanisms underlying this cancer protective effect remain unknown...
  27. ncbi request reprint Combination of serum biomarkers to differentiate malignant from benign ovarian tumours
    Gang He
    Department of Diagnostic Medicine, Jewish General Hospital, McGill University, Montreal, Quebec
    J Obstet Gynaecol Can 34:567-74. 2012
    ..To investigate biomarkers and clinical parameters to distinguish ovarian cancers from benign ovarian tumours...
  28. ncbi request reprint Cystectomy for immature teratoma of the ovary
    Mario E Beiner
    Department of Gynecologic Oncology, The Chaim Sheba Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Hashomer, 52621, Israel
    Gynecol Oncol 93:381-4. 2004
    ..In view of the lack of information concerning the outcome following cystectomy in germ cell tumors, we retrospectively evaluated the clinical outcome of patients who underwent cystectomy only as part of their surgical treatment...
  29. doi request reprint Outcome and quality of life in a prospective cohort of the first 100 robotic surgeries for endometrial cancer, with focus on elderly patients
    Zvi Vaknin
    Division of Gynecologic Oncology, Department of Nursing, Segal Cancer Center, Jewish General Hospital, Montreal, Quebec, Canada
    Int J Gynecol Cancer 20:1367-73. 2010
    ..Evaluation of surgical outcomes, including quality of life, in patients with endometrial cancer in the early phase of implementation of a robotic surgery program, comparing elderly with younger patients...
  30. doi request reprint Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer
    Roy Kessous
    Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, QC, H3T 1E2, Canada
    Gynecol Oncol . 2016
    ..To evaluate clinical outcome in patients selected to receive neoadjuvant chemotherapy (NACT) compared to primary debulking surgery (PDS)...
  31. pmc Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
    Maud Marques
    Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Cote Ste, Catherine Road, Montreal, QC, H3T 1E2, Canada
    BMC Med 13:217. 2015
    ..PARP inhibitors have shown promising clinical results in cancer patients carrying BRCA1/2 mutations. Their clinical efficacy could logically be influenced by PARP1 protein levels in patient tumors...
  32. pmc Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient
    Jian Zhang
    Department of Human Genetics, McGill University, Montreal, QC, Canada
    BMC Cancer 13:146. 2013
    ..Mutations in BRCA1 and BRCA2 genes are present in at least a fifth of patients. Uncovering other genes that become mutated subsequent to BRCA1/BRCA2 inactivation during cancer development will be helpful for more effective treatments...
  33. ncbi request reprint Sarcoma post-embolization for presumed uterine fibroids
    Karen Buzaglo
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, McGill University, SMBD Jewish General Hospital, 3755 Cote Ste Catherine Road, Montreal, Quebec, Canada H3T 1E2
    Gynecol Oncol 108:244-7. 2008
    ..It remains unclear whether a change in diagnostic work-up is required prior to uterine artery embolization in order to avoid missing sarcomas and delaying definitive treatment...
  34. doi request reprint Minimizing pain medication use and its associated costs following robotic surgery
    Jeremie Abitbol
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Gynecol Oncol . 2016
    ..The objective of the current study was to evaluate the use of analgesia in the post-operative period following robotic surgery for endometrial cancer...
  35. pmc Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors
    Oreekha Amin
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, 3755 Cote Ste Catherine Road, Montreal, H3T 1E2, QC, Canada
    BMC Cancer 15:817. 2015
    ..Further, we hypothesized that IGF-1R inhibition might sensitize HR proficient cancers to Poly ADP ribose polymerase (PARP) inhibitors...
  36. ncbi request reprint Para-aortic and Pelvic Radiotherapy, an Effective and Safe Treatment in Advanced-stage Uterine Cancer
    Alex Rabinovich
    Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
    Anticancer Res 35:2893-900. 2015
    ....
  37. pmc Targeting insulin and insulin-like growth factor pathways in epithelial ovarian cancer
    Marie Claude Beauchamp
    Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, QC, Canada H3T 1E2
    J Oncol 2010:257058. 2010
    ..In this paper, we will focus on the role of insulin/IGF in ovarian cancer tumorigenesis and treatment...
  38. ncbi request reprint Placental site trophoblastic tumor: outcome of five cases including fertility preserving management
    Ronit Machtinger
    Department of Gynecology Oncology, Division of Obstetrics and Gynecology, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
    Gynecol Oncol 96:56-61. 2005
    ..Placental site trophoblastic tumor (PSTT) is a rare variant of gestational trophoblastic disease that has been re-described during the 1970s...
  39. doi request reprint Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study
    Alex Rabinovich
    Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, Lady Davis Research Institute, Montreal, Quebec, Canada
    Acta Obstet Gynecol Scand 94:776-80. 2015
    ..Thus, in our group of patients, continued pegylated liposomal doxorubicin treatment was associated with a longer progression-free interval and allowed improved performance status with manageable toxicity...
  40. doi request reprint Advancing surgical simulation in gynecologic oncology: robotic dissection of a novel pelvic lymphadenectomy model
    Daniel J Kiely
    From the Departments of Gynecologic Oncology D J K, W H G, and Surgical Oncology W H G, McGill University Jewish General Hospital and Department of Gynecologic Oncology K J, McGill University Royal Victoria Hospital and Department of Gynecologic Oncology D J K, Centre Hospitalier de l Universite de Montreal, Hospital Notre Dame, Montreal, Quebec, Canada J Z P Division of Oncology and Pelvic Surgery, Pacific Gynecology Specialists, Seattle, WA
    Simul Healthc 10:38-42. 2015
    ....
  41. doi request reprint Hormonal and reproductive factors and the risk of ovarian cancer
    Anita Koushik
    Université de Montréal Hospital Research Centre CRCHUM, 850 Saint Denis Street, 2nd Floor, Montreal, QC, H2X 0A9, Canada
    Cancer Causes Control . 2017
    ..e., Type I/II invasive cancers) may contribute to a better understanding of etiology. We examined hormone-related factors in relation to ovarian cancer risk overall, for Type I and Type II cancers, as well as borderline tumors...
  42. doi request reprint Does hormonal therapy for fertility preservation affect the survival of young women with early-stage endometrial cancer?
    Zoë R Greenwald
    Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada
    Cancer . 2016
    ..The incidence of endometrial cancer among young women is increasing. Some patients with low-grade endometrial cancer receive hormone therapy (HT) before surgery to preserve fertility. It is unclear whether this adversely affects survival...
  43. doi request reprint Specimen quality evaluation in Canadian biobanks participating in the COEUR repository
    Cécile Le Page
    1 Centre Hospitalier de l Université de Montréal, Montreal, Quebec
    Biopreserv Biobank 11:83-93. 2013
    ....
  44. ncbi request reprint Granulocytic sarcoma presenting as tumors of the cervix
    Bhuvan Pathak
    Division of Gynecologic Oncology, Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2
    Gynecol Oncol 98:493-7. 2005
    ..Granulocytic sarcoma of the cervix, leading to the diagnosis of acute myelogenous leukemia (AML), is a rare event...
  45. ncbi request reprint Uterine smooth-muscle tumor of uncertain malignant potential metastasizing to the humerus as a high-grade leiomyosarcoma
    Adam Shapiro
    Division of Gynecologic Oncology, Sir Mortimer B Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada H3T 1E2
    Gynecol Oncol 94:818-20. 2004
    ..Most of these tumors have a benign clinical course, and coagulative tumor cell necrosis has usually been associated with worse outcome...
  46. ncbi request reprint Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors
    W H Gotlieb
    Division of Gynecologic Oncology, Sheba Medical Center, and Sackler School of Medicine, Tel Aviv University, Tel Hashomer, Israel
    J Natl Cancer Inst 90:995-1000. 1998
    ..To gain insight into these issues, we determined the rates of 185delAG-BRCA1 and 6174delT-BRCA2 mutations in patients with borderline ovarian tumors...
  47. ncbi request reprint Malignancies following bilateral salpingo-oophorectomy (BSO)
    W H Gotlieb
    Division of Gynecologic Oncology, Jewish General Hospital McGill University, Montreal, Canada
    Eur J Surg Oncol 32:1231-4. 2006
    ..Yet, a small subset of women develop primary peritoneal carcinomatosis (PPC) after BSO. The rates of PPC following non-risk reducing BSO have sparingly been reported...
  48. ncbi request reprint Prophylactic oophorectomy: clinical considerations
    W H Gotlieb
    Division of Gynecologic Oncology and the Suzanne Levy Gertner Oncogenetics Unit, Sheba Medical Center, Tel Hashomer, Israel
    Semin Surg Oncol 19:20-7. 2000
    ..Data concerning the benefit of prophylactic surgery, and the safety of established or innovative hormone replacement therapies in individuals at risk, are encouraging...
  49. ncbi request reprint Infertility treatment after conservative management of borderline ovarian tumors
    M E Beiner
    Department of Obstetrics and Gynecology, The Chaim Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, Israel
    Cancer 92:320-5. 2001
    ..Recurrences were observed in two of seven patients, all of which remained histologically borderline...
  50. ncbi request reprint Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer
    W H Gotlieb
    Division of Gynecologic Oncology, Tel-Aviv University, Tel-Hashomer, 52621, Israel
    Gynecol Oncol 82:99-104. 2001
    ..6 and 88.2% for Ki-67. CONCLUSIONS: Topoisomerase II expression as detected by immunohistochemistry in tumor samples emerged as a promising clinically relevant biomarker for survival in advanced epithelial ovarian cancer...
  51. ncbi request reprint Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello N 0310 Oslo, affiliated with the University of Oslo, Norway
    Cancer Metastasis Rev 22:103-15. 2003
    ..They also suggest the existence of a putative activation sequence of metastatic genes, involving the beta1 (and possibly alpha v) integrin subunits, IL-8, PEA3, Ets-1 and MMP in ovarian carcinoma...
  52. ncbi request reprint The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello 0310, Oslo, Norway
    Mol Cell Endocrinol 187:39-45. 2002
    ..05). We conclude that bFGF is the major angiogenic factor expressed in ovarian carcinoma at the mRNA level. MMP-2, MMP-9, MT1-MMP and TIMP-2 are valid markers of poor survival in advanced-stage ovarian carcinoma...
  53. ncbi request reprint PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma
    Ben Davidson
    Department of Pathology, The Norwegian Radium Hospital, Montebello, N 0310 Oslo, University of Oslo, Norway
    Clin Cancer Res 9:1412-9. 2003
    ..The purpose of this study was to analyze the possible correlation between PEA3 mRNA expression and survival in advanced-stage ovarian carcinomas, studying two patient groups with extremely different disease outcome...
  54. ncbi request reprint Genomic analyses of primary and metastatic serous epithelial ovarian cancer
    Ofir Israeli
    Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center, Tel Hashomer 52621, Ramat Gan, Israel
    Cancer Genet Cytogenet 154:16-21. 2004
    ..Our results imply that the major gross genetic changes in ovarian cancer take place in the primary tumor, and the additional genetic changes that may occur in the metastases are not detectable by CGH...